News | June 02, 2021
Lasa Supergenerics FY21 profit up 521%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company plans to enter the EU markets in FY22
Dr. Reddy's has the rights to distribute 250mn doses in India
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
